Actually, the clinical trials of FAP-targeting radiotherapy are ongoing in patients with different types of cancer, including nasopharyngeal carcinoma and pancreatic adenocarcinoma [85,86]. This evidence concerns the gene FAP and nasopharyngeal carcinoma.